alpha 1D adrenergic receptor Agonists
1 drugsAbout alpha 1D adrenergic receptor
The alpha 1D adrenergic receptor (α1D-AR) is a G protein-coupled receptor that mediates the effects of norepinephrine and epinephrine. It is a subtype of the alpha-1 adrenergic receptor family. α1D-AR plays a crucial role in various physiological processes.
Tamsulosin hydrochloride, an antagonist of α1D-AR, is used to treat benign prostatic hyperplasia (BPH). By blocking the receptor in the prostate and bladder neck, it relaxes smooth muscle and improves urine flow. Currently, there is no genetic evidence data available linking this target to specific diseases.
α1D-AR is targeted by one FDA-approved drug, tamsulosin hydrochloride. This drug is a small molecule developed by Novartis. The therapeutic area for drugs targeting this receptor is classified as "Other", reflecting its primary application in urological conditions.
Top alpha 1D adrenergic receptor Drugs
Novartis is the primary company in this space, holding the approval for tamsulosin hydrochloride.
High market concentration suggests significant barriers to entry; consider strategic partnerships.
alpha 1D adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha 1D adrenergic receptor, using small molecule modality.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing treatments.
alpha 1D adrenergic receptor Clinical Trials 73 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alpha 1D adrenergic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 9 | 0 | 1 | 100% |
| Phase 2 | 11 | 6 | 0 | 5 | 100% |
| Phase 3 | 20 | 10 | 6 | 4 | 63% |
| Phase 4 | 32 | 21 | 6 | 5 | 78% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha 1D adrenergic receptor Drug Approval Timeline (2010 - 2010)
The first and most recent drug approval for this target was tamsulosin hydrochloride in 2010.
The lack of recent approvals indicates potential saturation or challenges in developing new α1D-AR targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 55 (14 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alpha 1D adrenergic receptor. A trial counts if an approved drug acting on alpha 1D adrenergic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.